Slideshows Images Quizzes

Anoro Ellipta

Last reviewed on RxList: 10/27/2017
Anoro Ellipta Side Effects Center

Last reviewed on RxList 10/27/2017

Anoro Ellipta (umeclidinium and vilanterol) Inhalation Powder is a combination anticholinergic and long acting beta-adrenoceptor agonist (LABA) used for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Common side effects of Anoro Ellipta include:

  • sore throat,
  • sinusitis,
  • respiratory tract infection,
  • constipation,
  • diarrhea,
  • pain in extremities,
  • muscle spasms,
  • neck pain,
  • chest pain or discomfort,
  • cough,
  • indigestion,
  • abdominal pain,
  • gastroesophageal reflux disease (GERD),
  • vomiting,
  • weakness,
  • irregular heart beats,
  • itching,
  • rash,
  • conjunctivitis,
  • palpitations,
  • hypersensitivity reactions including anaphylaxis and hives,
  • changes in taste,
  • tremor, and
  • anxiety.

Anoro Ellipta is administered as 1 inhalation dose once daily by the orally inhaled route only. Anoro Ellipta may interact with monoamine oxidase inhibitors (MAOIs), antidepressants, beta blockers, diuretics, and other anticholinergic drugs. Tell your doctor all medications and supplements you use. During pregnancy, Anoro Ellipta should be used only if prescribed. Tell your doctor if you are pregnant before taking Anoro Ellipta or if you become pregnant during treatment. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Anoro Ellipta (umeclidinium and vilanterol) Inhalation Powder Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Anoro Ellipta Professional Information


LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. ANORO ELLIPTA is not indicated for the treatment of asthma. [See BOXED WARNING and WARNINGS AND PRECAUTIONS]

The following adverse reactions are described in greater detail in other sections:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The clinical program for ANORO ELLIPTA included 8,138 subjects with COPD in four 6-month lung function trials, one 12-month long-term safety study, and 9 other trials of shorter duration. A total of 1,124 subjects have received at least 1 dose of ANORO ELLIPTA (umeclidinium/vilanterol 62.5 mcg/25 mcg), and 1,330 subjects have received a higher dose of umeclidinium/vilanterol (125 mcg/25 mcg). The safety data described below are based on the four 6-month and the one 12-month trials. Adverse reactions observed in the other trials were similar to those observed in the confirmatory trials.

6-Month Trials

The incidence of adverse reactions associated with ANORO ELLIPTA in Table 1 is based on four 6-month trials: 2 placebo-controlled trials (Trials 1 and 2; n = 1,532 and n = 1,489, respectively) and 2 active-controlled trials (Trials 3 and 4; n = 843 and n = 869, respectively). Of the 4,733 subjects, 68% were male and 84% were white. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean postbronchodilator percent predicted forced expiratory volume in 1 second (FEV1) was 48% (range: 13% to 76%), the mean postbronchodilator FEV1/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%).

Subjects received 1 dose once daily of the following: ANORO ELLIPTA, umeclidinium/vilanterol 125 mcg/25 mcg, umeclidinium 62.5 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, active control, or placebo.

Table 1: Adverse Reactions with ANORO ELLIPTA with ≥1% Incidence and More Common than Placebo in Subjects with Chronic Obstructive Pulmonary Disease

Adverse Reaction ANORO ELLIPTA
(n = 842)%
Umeclidinium 62.5 mcg
(n = 418) %
Vilanterol 25 mcg
(n = 1,034) %
(n = 555) %
Infections and infestations
Pharyngitis 2 1 2 <1
Sinusitis 1 <1 1 <1
Lower respiratory tract infection 1 <1 <1 <1
Gastrointestinal disorders
Constipation 1 <1 <1 <1
Diarrhea 2 <1 2 1
Musculoskeletal and connective tissue disorders
Pain in extremity 2 <1 2 1
Muscle spasms 1 <1 <1 <1
Neck pain 1 <1 <1 <1
General disorders and administration site conditions
Chest pain 1 <1 <1 <1

Other adverse reactions with ANORO ELLIPTA observed with an incidence less than 1% but more common than placebo included the following: productive cough, dry mouth, dyspepsia, abdominal pain, gastroesophageal reflux disease, vomiting, musculoskeletal chest pain, chest discomfort, asthenia, atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, pruritus, rash, and conjunctivitis.

12-Month Trial

In a long-term safety trial, 335 subjects were treated for up to 12 months with umeclidinium/vilanterol 125 mcg/25 mcg or placebo. The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy trials described above. Adverse reactions that occurred with a frequency of greater than or equal to 1% in the group receiving umeclidinium/vilanterol 125 mcg/25 mcg that exceeded that in placebo in this trial were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.

Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of ANORO ELLIPTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to ANORO ELLIPTA or a combination of these factors.

Cardiac Disorders


Eye Disorders

Blurred vision, glaucoma, increased intraocular pressure.

Immune System Disorders

Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria.

Nervous System Disorders

Dysgeusia, tremor.

Psychiatric Disorders


Renal and Urinary Disorders

Dysuria, urinary retention.

Respiratory, Thoracic, and Mediastinal Disorders

Dysphonia, paradoxical bronchospasm.

Read the entire FDA prescribing information for Anoro Ellipta (Umeclidinium and Vilanterol Inhalation Powder)

Related Resources for Anoro Ellipta

© Anoro Ellipta Patient Information is supplied by Cerner Multum, Inc. and Anoro Ellipta Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors